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2ABSTRACT 
Objective:  We investigated the influence of hormone therapy (HT) on submaximal 
central and peripheral function in healthy postmenopausal women (PMW) after 12 weeks 
of endurance training. Design: A randomized double-blind placebo-controlled study in a 
research and clinical facility was conducted. All subjects (n=23) underwent 12 weeks of 
aerobic exercise training (walking 5d/week at 70-80% peak heart rate).  Eleven subjects 
received HT, 12 received placebo.  HT consisted of daily 17 beta-estradiol (1 mg) with 
cyclic micronized progesterone (200 mg) or placebo for 10 days per month.  Subjects 
were tested pre- and post- exercise training.  Primary outcome measures were 
submaximal stroke volume (SV), cardiac output, and total peripheral resistance (TPR) 
measured during cycling at 30W, 45W, and 60W. Secondary outcome measures were 
ventilatory threshold (VT), peak oxygen uptake (VO2 peak), and resting and peak-
ischemic calf blood flow.  Results: At baseline, HT and placebo groups were similar 
(P>0.05) in age (57 ± 1 years; mean ± SEM), height (162 ± 2 cm), weight (72 ± 4 kg), 
VO2 peak (21.5 ± 1.4 ml•kg
-1•min-1), and all cardiovascular measures. Post-training 
oxygen consumption and heart rate decreased (P<0.05) within groups during each 
submaximal exercise workload. SV, cardiac output and TPR remained unaltered 
(P>0.05). VO2 peak and oxygen consumption at the VT increased (P<0.05) within 
groups.  Resting and post-ischemic blood flow were unaltered. HT did not influence any 
of the cardiovascular responses. Conclusions: These findings suggest that in healthy 
PMW, 12 weeks of aerobic training is effective in eliciting favorable cardiovascular 
adaptations, regardless of the presence of short-term HT. 
3Keywords: cardiovascular, estrogen, stroke volume, cardiac output, blood flow.
4INTRODUCTION  
Exercise training is strongly recommended in post-menopausal women (PMW) to reduce 
coronary artery disease (CAD) risk1, 2 to counter the effects of osteoporosis 3, 4 and to 
improve body composition and overall health.5  Endurance-trained women have a 
significantly lower risk for all-cause mortality and nonfatal cardiovascular events.6  In 
addition, regular aerobic exercise is linked to enhanced vascular function, including 
decreased arterial stiffness7-9 and improved endothelial function.10 Inceased arterial 
stiffness and endothelial dysfunction are independently and in combination linked with 
increased cardiovascular disease risk.7-10 Similar to the benefits of exercise, estrogen 
administration in healthy PMW is also associated with improved endothelial function,11
and decreased arterial stiffness.7 Despite early reports of estrogen administration 
reducing the risk of coronary heart disease,12 recent randomized placebo-controlled trials 
reported either no benefit or an increased rate of cardiac events with hormone therapy 
(HT).13, 14  Discordance between findings from observational studies and randomized 
control trials are suggested to be related to the type and timing of HT relative to the onset 
of menopause.15, 16 In support of this ‘timing hypothesis’,16 recent re-analysis of data 
from the WHI14 has shown that younger and recently PMW (50-59 years of age) have 
lower absolute risks for adverse outcomes from HT initiation than do older and long after 
PMW.17 Randomized clinical trials are currently underway to specifically investigate the 
cardiovascular effects of HT and 17 beta-estradiol in recently PMW.18, 19 Meanwhile, the 
administration of HT in women for the relief of menopausal and uro-genital symptoms to 
avoid fractures and atrophy of connective tissue continues to be advocated.20
5In light of the recommendation for PMW to participate in regular aerobic exercise 
to elicit numerous health benefits, and that approximately 28% of PMW aged 50-74 years 
are still prescribed HT in the US alone,21 potential cardiovascular interactions between 
these interventions are of clinical relevance. Knowledge of such interactions would help 
guide practitioners and patients toward appropriate HT and exercise decisions. However, 
the interaction between HT and cardiovascular hemodynamics in response to exercise 
training is not well understood in general, in particular whether cardiovascular responses 
and adaptations to exercise training differ among users and non-users of HT. Although 
improvements in peak and submaximal cardiovascular parameters, such as stroke volume 
and cardiac output, in response to short-term endurance training have previously been 
shown to be independent of HT status in health 22 and disease,23 no controlled studies 
have been reported. As such, the purpose of this study was to examine the influence of 
HT on central and peripheral function before and after 12 weeks of aerobic exercise 
training using a randomized, placebo control design in healthy PMW. Considering the 
well known benefits of estrogen on vascular function,7, 11, 24 it was hypothesized that HT 
would confer greater improvements to central and peripheral measures of 
cardiovascular function compared with non-users.
METHODS
Study Design:  A randomized, double-blind, placebo-controlled, exercise-training study 
was conducted.  Following medical screening, subjects were randomly assigned to either 
HT or placebo control group (N-HT), with physiological assessmements made at baseline 
and after 12 weeks of aerobic training.  The Human Research and Ethics Committee at 
6the University of Toronto approved the study protocol and written consent was obtained 
from all subjects following the principles of the Helsinki Declaration.
Study Population:  Subjects included PMW who had undergone natural or surgical 
menopause and were amenorrheic for at least one year.  Subjects were recruited through 
gynecologist physician referral, and through local newspaper advertisements.  The 
number of years since menopause was not recorded.  A total of 37 PMW were recruited 
over a one year period.  A total of 14 (38%) subjects either dropped out of the study or 
were excluded due to non-compliance to the exercise training for various reasons, 
including time commitment (n=6), illness (n=6), and orthopadic conditions that limited 
their ability to walk (n=2).  There were no drop-outs associated with the HT. A total of 23 
subjects completed the study, 11 of which received HT and 12 received placebo (N-HT).   
Since we have previously demonstrated unaltered central cardiovascular function during 
submaximal aerobic exercise in response to 12 weeks of HT alone in healthy PMW,24 we 
did not examine the independent effects of HT in the current study.
Eligibility Criteria:  Serum estradiol (E2) and follicle-stimulating hormone (FSH) levels 
confirmed postmenopausal status (FSH>40 IU/L; E2 <80 pmol/L).
24 Eligible subjects 
were healthy, sedentary and had not performed regular exercise for at least 1 year. 
Exclusion criteria included diagnosed diabetes mellitus, use of any cardiac medications or 
any orthopaedic conditions likley to impede the ability to participate in exercise training 
and testing.  
7Randomization:  Subjects were randomized to either treatment or placebo groups and 
performed baseline measures prior to drug assignment, after which subjects were given 
their package of pills for the study, consisting of either 1mg oral 17β-estradiol or placebo. 
200mg of micronized progesterone, or placebo, were administered for those with and 
without an intact uterus, respectively, for a period of 10 days/month.  This medication 
phase was positioned at approximately 3 weeks, after each estradiol treatment, for a total 
of three months. To minimize the effects of the progesterone, post-HT cardiovascular 
measures were obtained during the very last week of estradiol treatment. Subjects were 
instructed to talk to the study physician, who was readily available, should they wish to 
discuss any symptoms or ask any questions regarding the HT treatment, and not to share 
this information with the research team. 
Anthropometry:  Adiposity measures included body mass index (BMI), and waist and hip 
circumference.  The sum of skinfolds (mm; John Bull, British Indicators) were obtained 
from three sites: suprailiac, triceps, and subscapular regions with percent body fat 
estimations calculated using standard equations.25
Blood Analysis:  Blood samples, performed at the same time of day (08:00 am – 12:00 
pm) during each visit to the laboratory, were drawn from the antecubital vein using 
standard venipuncture techniques.  Serum E2, total testosterone and progesterone were 
assessed in duplicate using competitive immunoassay methods (Ortho-Clinical 
Diagnostics Inc., Vitros Immunodiagnostic Products, Rochester, NY).  Sex-hormone 
binding globulin (SHBG) was assessed using chemiluminescent immunometric assay 
8methods (Immulite, Diagnostics Products Corporation, Los Angeles, CA).  Serum was 
stored at –20 C, and all samples were run in the same assays to eliminate contributions 
from inter-assay assay variance. All intra-assay CVs were <8%. Assay sensitivities were 
10 pmol/L for E2, 0.25 nmol/L for progesterone, less than 0.03 nmol/L for testosterone,
and 0.02 nmol/L for SHBG. Free androgen index (FAI) was calculated using the ratio of 
total testosterone to the concentration of SHBG.26
Graded Exercise Testing:  Graded exercise to maximal effort was performed on an 
electrically braked cycle ergometer (Ergoline Ergometrics 800S) using standard open-
spirometry techniques.  Protocol included a 1-min warm-up at zero load, with work rate 
increased by 15 W/min until exhaustion. An automated sphygmomanometer was used to 
record blood pressure each minute (Tango, Sun Tech Medical Instruments). Measures of 
peak oxygen uptake (VO2 peak), minute ventilation, ventilatory threshold (VT), peak 
work rate, and peak heart rate were obtained as described previously by our group.24 The 
VT was determined using the break point in the ventilatory equivalent.27
Cardiac Output and Total Peripheral Resistance: A second exercise test was used to 
determine cardiac output (Q) during exercise using the equilibrium CO2 rebreathing 
technique.28  Three submaximal workloads of 30, 45, and 60 W (corresponding to ~40, 
50, and 60% of peak work rate, respectively) were assessed. Stroke volume (SV; ml) was 
determined as Q divided by heart rate (HR; beats/min).  Total peripheral resistance 
(dynes/sec/cm-5) was calculated as (mean arterial pressure[mmHg]/Q[L/min]) × 80.
9Skeletal Muscle Blood Flow: Resting calf blood flow (BF) and peak flow-mediated 
vasodilatory capacity were measured in the supine position using venous occlusion 
strain-gauge plethysmography (Vasculab SPG16, Medasonics, Mountain View, CA) as 
described previously.24, 29  Briefly, an indium-gallium strain gauge was used with an 
occlusion cuff excluding BF to the foot. To produce maximal flow-mediated peripheral 
vasodilation both cuffs were inflated to 200 mmHg for 3-mins, followed by ischemic 
plantar flexion exercise to fatigue on a specialized ergometer. BF was measured from the 
slope of the time-leg volume curve. Vascular conductance (G) was calculated as 
BF/mean arterial pressure (MAP). Test-retest reliability for BF measures in our 
laboratory yielded an intra-class correlation alpha =.91 for peak BF and 0.90 for resting 
BF. HR, MAP, and blood pressure were recorded from the middle finger on a beat-to-
beat basis using the Finapres method (Finapres, Ohmeda, Englewood, CO). 
Exercise Training:  Exercise Training consisted of walking five days per week, with at 
least one supervised session per week.  Each exercise session composed of a 10-minute 
warm-up, a 45 minute aerobic conditioning (walking) session, and a 10-minute cool 
down.  For the first two weeks, subjects were prescribed a walking intensity of 70% peak 
HR (~55% VO2 peak), with training intensities increased to 75-80% peak HR (65-75% 
VO2 peak).
30  
Compliance: Treatment compliance was confirmed via pill counts at each testing time 
point and cross-referenced to serum hormone blood values.  Exercise training compliance 
was confirmed by individual weekly training diaries, including completed distance 
10
(number of laps), total aerobic conditioning time, exercise HR, and subjective feelings.  
Failure to maintain 75% of the weekly prescription resulted in exclusion from the study 
sample.
Data Analysis: The data were analyzed using the Statistical Package for the Social 
Sciences (SPSS Inc., Chicago. IL), version 11.  The following calculation was used to 
determine the number of observations needed to provide an 80% probability of finding 
differences of 1.5 standard deviations in two-sample tests confirming the effects of HT 
and exercise at a significance level of 0.05:31
n = 2 * (tdf=21α=0.05 + t
df=21
β=0.20)
2 * (SD/d)2 = 2 * (2.08 + 1.32)2 * (1/1.5)2 = 10
Paired t-tests were used for overall effects, and independent t-tests for the differences 
between groups (HT and N-HT) at baseline.  Effects of exercise were calculated as post-
exercise training measures vs. baseline measures.  Independent t-tests were used to detect 
differences in effects of exercise training between groups (HT and N-HT).  The 
Bonferroni correction was applied for multiple comparisons. All data are reported as 
means ± standard error of the mean (SEM), and are considered statistically significant at 
P<0.05. 
RESULTS
Subject Characteristics: Baseline subject characteristics are presented in Table 1.  Groups 
were similar (P>0.05) in age, height, weight, percent body fat, lean body mass, total fat 
mass, and body mass index.  Significant reductions (P<0.05) in waist circumference, 
11
percent body fat, and total fat mass were observed within, but not between, groups post-
exercise training.  Body mass was not altered (P>0.05) after 12 weeks of exercise 
training.
Serum Hormones:  There were no significant differences in serum hormone measures 
between the groups at baseline (see Table 2).  As expected, serum E2 concentration 
increased significantly (P<0.05) from 43.6±3.5 pmol/L to 581.4±65.3 pmol/L after three 
months in the HT group, but did not increase in the placebo group.  Progesterone and 
testosterone levels did not increase in either group. FAI (arbitrary units) decreased 
significantly from 1.49±0.2 to 0.72± 0.1 in the HT group (P<0.05), reflecting the 
significant changes found in SHBG (37.9±0.4 to 77.8±4.7 nmol/L) with HT.  SHBG did 
not change in the placebo group.   
Compliance:  Pill counts confirmed compliance (100%) and were confirmed against 
hormone levels. The HT and placebo groups had a similar training HR (beats/min) at 
baseline (119±3 vs. 114±2), after two months (122±3 vs. 116±2), and after three months 
(123±2 vs. 117±2), as assessed during each training session.  Total weekly distance (km) 
walked was also similar between groups after one, two and three months of training, 
respectively (4.3±0.2 vs. 4.4±0.1, 4.7±0.2 vs. 4.7±0.1, and 5.0±0.2 vs. 5.2±0.2, for HT vs. 
N-HT, respectively).  Training speed (km/hr) ranged between 4.6-4.8 for HT users, and 
between 4.6-4.7 for non-users (P>0.05). Frequency of training sessions did not differ 
between groups (P>0.05), with both groups attaining ~85-95% of prescribed distances 
(P>0.05).  
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Submaximal Cardiovascular Responses:  Data for Q, SV, HR and total peripheral 
resistance (TPR) during 30W and 60W workloads are presented in Table 3.  There were 
no differences in physiological responses between groups, nor did HT influence any of 
the examined variables.  In the sample as a whole, there was a significant training-
induced lowering of HR at each of the 3 workloads (30W, P=0.002; 45W, P=0.002 [data 
not shown]; 60W, P=0.001), along with a modest decrease in VO2 at 30W (P=0.014) and 
60W (P=0.040) in the group as a whole after training.  There were no significant 
(P>0.05) changes in Q or calculated SV at any submaximal workload in either group. 
Peak Oxygen Uptake and Ventilatory Threshold:  VO2 peak and VT increased similarly 
between HT and N-HT groups (Figure 1).  Mean VO2 peak (ml•kg
-1•min-1) at baseline 
(22.01±1.12) increased by ~9% after 12 weeks (24.34±1.36) in the HT group.  Similarly, 
N-HT women increased VO2 peak ~14% after 12 weeks from 21.06±1.72 to 23.45±1.48, 
matching the HT group’s rate of increase.  Similar changes were observed for the VT 
(ml•kg-1•min-1), which increased significantly (P<0.05) within, but not between, groups. 
The HT group (13.10±0.46) increased  ~9% after 12 weeks (14.96±0.97), with 
corresponding VT values for the N-HT group being 11.90±1.31 to 12.17±1.09, 
representing an ~5% increase.  These increases were independent of HT status. 
Peak HR, peak MAP, and VT HR were not significantly different (P>0.05) within 
or between groups at baseline or after 12 weeks of training.  Peak and VT workload 
(watts) were also similar (P>0.05) at baseline and after 12 weeks of training.  
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Peripheral Vascular Function:  Resting and peak-ischemic BF responses were similar 
(P>0.05) at baseline.  Increases in peak-ischemic BF failed to reach statistical 
significance after exercise training (P=0.09) and was not influenced by HT (P=0.43).  
Similarly, both groups demonstrated comparable (P>0.05) resting MAP and G at 
baseline, without any alteration after training.  Baseline peak-ischemic vascular resistance 
was also similar (P>0.05) between groups, with peak-ischemic G increasing significantly 
(P<0.05) within groups after training (0.39±0.03 to 0.46±0.03 in HT, and 0.37±0.03 to 
0.39±0.04 N-HT; Figure 2).  Using pooled data from both groups, improvements in peak-
ischemic G showed a significant effect of exercise (P=0.032), but not for HT (P=0.213).   
DISCUSSION
In the current study we demonstrate that 12 weeks of moderate aerobic exericse training 
is equally effective in conferring beneficial central and peripheral cardiovascular 
adaptations in users and non-users of short-term HT in healthy PMW.  Post training we 
observed decreased oxygen consumption and HR during each submaximal exercise 
workload, but SV, cardiac output and TPR were unaltered in both groups. VO2 peak and 
oxygen consumption at the VT were also increased in both groups.  The gains in VO2 
peak occurred in the absence of central (cardiac) adaptation(s), although modest 
improvements in peripheral hemodynamics were observed.  Collectively, our findings 
suggest that a short-term endurance exercise intervention in healthy PMW elicits 
similarly favorable cardiovascular health gains in users and non-users of short-term HT.  
Increased VO2 peak in response to three months of aerobic training is consistent 
with the widely-known physiologic adaptations seen with regular endurance exercise. 
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Despite the well documented vasoregulatory effects of estrogen, HT did not confer a 
greater response. This is, in part, in contrast with evidence supporting an effect of HT on 
aerobic capacity in sedentary PMW.32  It is possible, however, that the net effect of 
exercise training may be sufficient to overwhelm any subtle effects conferred by HT.    
Our observed exercise training-dependent increase in VO2 peak (~9%) was similar to that 
reported by Lindheim and colleagues 33 after 6 months of endurance training in PMW 
(range = 42-59 years) with and without HT, training 3 days a week for 30-mins at 70% 
HR peak.  Others have also reported no effect of varying hormonal preparations and 
dosages of HT on VO2 peak after endurance training.
22, 34-36 Similarly, studies 
demonstrate no effect of short-term HT alone on peak oxygen uptake in healthy PMW 
not undertaking exercise training.24, 37, 38  Collectively, these data and ours support little 
or no effect of HT on peak oxygen uptake, irrespective of exercise training. 
Our findings indicate that HT does not influence measures of SV, Q, TPR or 
calculated arterio-venous oxygen difference during submaximal exercise in healthy PMW 
undergoing short-term endurance training.  These findings are consistent with cross-
sectional data reporting that long-term (>2 years) HT fails to influence SV, Q, HR, TPR 
and arterio-venous oxygen difference across a range (40, 60 and 80% VO2 peak) of 
submaximal exercise intensities among age-matched older (~63 years) sedentary, 
regularly physically active and athletic PMW.36  Similarly, others demonstrate that long-
term (>1 year) HT is not associated with alterations in submaximal (60% of VO2 peak) 
SV, Q, and arterio-venous oxygen difference after 20 weeks of aerobic training (55-75% 
of VO2 peak) in healthy young (~55 years) PMW.
22  These data, and ours, suggest that 
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HT both short- and long-term, does not alter central hemodynamic responses during 
submaximal exercise in aerobically trained and untrained PMW.
Given our failure to detect any influence of HT on central hemodynamic 
responses, we collapsed the data to compare the exercise training-dependent effects with 
other studies in PMW.  Consistent with an effect of regular aerobic training, we observed 
a decrease in VO2 and HR at each exercise intensity workload after 12 weeks of training. 
However, we did not observe changes in Q, SV, MAP, TPR or arterio-venous difference.  
These changes are both consistent 39, 40 and inconsistent 22, 36 with previous studies.  For 
example, Spina and colleagues 40 reported no change in submaximal SV in conjunction 
with an increase in arterio-venous content difference in healthy older PMW (63±4 years) 
after nine months of endurance training.  Conversely, after 20 weeks of endurance 
training in younger (~55 years) PMW, Green et al.,22 observed a significant increase in 
SV reported at 60% of VO2 peak and at 50W.  This group 
22 also reported significant 
decreases in submaximal VO2, HR and Q.  In athletic, but not recreationally physically 
active PMW, McCole and colleagues 36 reported exercise training dependent gains in 
VO2, Q, and SV.  While the interaction between exercise training duration and exercise 
intensity on submaximal central adaptations are unclear, these studies suggest that 
improvements in central hemodynamic responses during exercise are greatly effected by 
exercise intensity, with higher intensity mediating greater improvements.  
Despite evidence that HT has been shown to restore peripheral BF, 24, 41 vascular 
conductance, 24, 41 endothelium-dependent vasodilation 11 and total peripheral resistance 
42, 43 in estrogen deficient PMW, we detected only modest non-significant gains in resting 
and peak-ischemic calf blood flow, and TPR.  It is possible that our discordant findings 
16
may be due to the attenuation of estrogen-mediated vasodilation by progesterone.44  
Indeed, this could be an important factor in other studies reporting little or no effect of 
HT on submaximal hemodynamics.  However, since we positioned testing at the farthest 
possible time-point from the progesterone administration (3 weeks), it is unlikely to have 
impacted our results.  
The effects of aerobic exercise training on peripheral BF in PMW are unclear. We 
observed no significant effect of exercise training on BF. This is, in part, comparable 
with studies reporting no change in resting BF after 31 weeks of a walk/jog program at 
70-90% of VO2 peak for 45 minutes, 3-5 days per week in older (65±3 years) healthy 
PMW.45  Conversely, peak ischemic blow flow has been shown to increase ~18% 45 and 
~40% 46 in response to 32 weeks of endurance training.  The greater increases in peak-
ischemic blood flow reported by Martin et al.,45 compared to that found in the current 
study is likely due to the longer and more intense training program. 
Limitations
Our sample size is small, and as such, we may be underpowered to detect subtle 
differences between groups.  Consequently, our findings should be interpreted with 
caution.  The exclusion of an HT-only group in the present study also meant we could not 
examine the independent effects of short-term HT alone on central and peripheral 
function. It is possible our low-dose hormone regimen may not have been sufficient to 
confer improvement to central and peripheral function. Alternative hormonal 
preparations, dosages and/or duration of treatment may have impacted our parameters of 
interest differently. Of interest, recent studies have also indicated underlying vascular 
17
changes among women reporting hot flashes.47  Since we did not document whether our 
PMW were experiencing vaso-motor symptoms we were not able to determine the effects 
of hot flashes on our cardiovascular measures.  Finally, although frequency, distance 
walked and exercise intensity were not reported to be different between the groups, 
absence of full supervision of the exercise training sessions may have also have affected 
our findings.
Conclusions
This study demonstrates that 12 weeks of aerobic training at a moderate intensity 
is equally effective in conferring increases to VO2 peak and VO2 at VT in users and non-
users of short-term HT in healthy PMW.  This finding suggests that in the absence of 
disease, short-term HT does not influence peripheral or central cardiovascular 
adaptations.   Further randomized controlled studies examining the long-term effects of 
HT and endurance training in women who have recently undergone menopause compared 
with those who are long-after the menopausal transition will help clarify the potentially 
independent and combined effects of these interventions in health and disease.  
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FIGURE LEGENDS
Figure  1. Oxygen uptake at VT (a) and VO2 peak (b) in the study groups before and 
after three months of aerobic training.  *P<0.05 from baseline within groups. No 
significant differences were detected between groups for VT and VO2 peak pre- and post-
exercise training.
Figure 2. Peak ischemic vascular conductance (a) and calf blood flow (b) in the study 
groups before and after three months of aerobic training.  * P<0.05 from baseline within 
both groups.  § P=0.056 within the group. No differences were observed between groups.
Table 1. Baseline characteristics of the study groups. 
 
  HT N-HT 
  n = 11 n = 12 
Age (years) 55 ± 1 58 ± 2 
Height (cm) 162.6 ± 2.5 161.5 ± 1.3 
Weight (kg) 72.7 ± 4.7 71.8 ± 4.2 
Waist (cm) 84.6 ± 3.1 87.8 ± 3.2 
Body Fat (%) 37.6 ± 1.9 38.7 ± 1.2 
LBM (kg) 44.6 ± 1.9 43.5 ± 1.9 
FM (kg) 28.2 ± 2.9 28.2 ± 2.4 
BMI (kg/m
2
) 27.5 ± 1.7 27.5 ± 1.5 
Values are mean ± SEM. 
LBM, lean body mass; FM, fat mass; BMI, body mass index. 
 
Table 1
Table 2. Baseline serum hormone levels of the study groups. 
  HT N-HT 
  n = 11 n = 12 
E2 (pmol/L) 43.6 ± 3.5 40.1 ± 0.7 
Progesterone (nmol/L) 0.3 ± 0.1 0.2 ± 0.1 
SHBG (nmol/L) 37.9 ± 3.6 46.9 ± 5.9 
Testosterone (nmol/L) 0.5 ± 0.1 0.6 ± 0.1 
Free Androgen Index 1.5 ± 0.2 1.4 ± 0.2 
FSH (IU/L) 83.4 ± 4.1 91.9 ± 4.7 
Values are mean ± SEM. 
E2, estradiol; SHBG, sex-hormone binding globulin; FSH, follicle stimulating hormone. 
Table 2
1Table 3. Submaximal cardiovascular responses to two different cycle ergometer workloads for HT and N-
HT at baseline and after 3 months of aerobic exercise training.
HT (n=11) N-HT (n=12)
Baseline Post-Training Baseline Post-Training
30W 
VO2 (L/min) 0.69 ± 0.03 0.63 ± 0.02* 0.67 ± 0.03 0.65 ± 0.03*
Cardiac Output (L/min) 6.52 ± 0.40 6.27 ± 0.33 6.60 ± 0.22 6.59 ± 0.44
HR (beats/min) 109 ± 4 103 ± 3* 106 ± 4 102 ± 3*
SV (ml) 61.00 ± 5.66 61.69 ± 3.98 63.08 ± 2.63 64.88 ± 3.65
MAP (mmHg) 100 ± 3 96 ± 4 102 ± 3 103 ± 4
TPR (dynes/s/cm-5) 15.89 ± 1.03 15.68 ± 0.73 15.55 ± 0.67 16.12 ± 0.91
a-v O2 difference 108.07 ± 5.53 101.50 ± 3.04 102.38 ± 3.87 100.31 ± 3.36
60W 
VO2 (L/min) 1.01 ± 0.04 0.95 ± 0.03* 0.99 ± 0.04 0.96 ± 0.04*
Cardiac Output (L/min) 8.31 ± 0.35 8.16 ± 0.28 8.62 ± 0.29 8.84 ± 0.47
HR (beats/min) 128 ± 4 121 ± 4* 124 ± 3 118 ± 3*
SV (ml) 65.97 ± 4.23 68.36 ± 3.35 70.32 ± 3.13 74.41 ± 2.75
MAP (mmHg) 112 ± 4 112 ± 3 120 ± 3 118 ± 4
TPR (dynes/s/cm-5) 13.59 ± 0.49 13.82 ± 0.53 14.12 ± 0.50 13.59 ± 0.48
a-v O2 difference 121.74 ± 3.27 117.25 ± 3.71 115.15 ± 3.57 110.70 ± 5.24
All values are mean ± SEM.  
VO2, oxygen consumption; HR, heart rate; SV, stroke volume; MAP, mean arterial pressure; TPR, total 
peripheral resistance.  * P<0.05 compared to baseline within groups.  HT did not influence any 
cardiovascular measure.  There were no differences between groups.
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Boston, MA 02114
November 30, 2008
Dear Dr Schiff:
Thank for your email and reviewer comments regarding our paper ‘Aerobic Exercise 
Training in Healthy Postmenopausal Women: Effects of Hormone Therapy’.  We have 
attempted to address each concern individually and have amended the manuscript 
accordingly.  Please see below our responses to each reviewer.  We look forward to 
receiving your feedback.  
Yours sincerely,
Dr Jack M Goodman
Cardiovascular Research Laboratory, 
Department of Exercise Sciences, University of Toronto, 
55 Harbord Street, Toronto, Ontario, Canada, M5S 2W6.  
Tel: 416-978-0762, Fax: 416-946-8116, Email: jack.goodman@utoronto.ca
Reviewer 1
General Comments to Authors
The study by O'Donnell et al compared a small group of PMW who underwent aerobic 
training for 12 weeks with another small group who were randomly put on HT as well. 
The investigators measured or calculated a long list of parameters related to exercise and 
cardio-respiratory function. It seems that the study was carefully planned and executed 
and the results are of interest. However, my philosophy is that an article should serve the 
readers rather than the investigators. If this article would have been submitted to a
cardiology journal, the following comment would not have to be made. However, the 
format and phrasing of a manuscript sent to a journal designated for a general readership 
should be adapted accordingly. Most of Menopause readership would find such article 
too long, too detailed, and perhaps too difficult to understand.
Authors Response to General Comments
We thank the reviewer for his/her comments.  In order to facilitate greater understanding 
for the readership of Menopause, we have modified the methods and relevant aspects of 
the discussion to amplify the message regarding cardiovascular function and health.  
Specifically, the length, phrasing and formatting of the manuscript have been adjusted for 
*Response to Reviewers
the general readership as the reviewer suggests. We trust this now reflects a balanced and 
relevant approach.
Comments to Author
1) there is a growing body of evidence suggesting that the cardio-vascular reactions to 
HT may differ among flushers and non-flushers. In a small group of examinees, this 
might be a limitation since there is no information on the percentage of flushers. 
Additionally, there might be a difference between women with an intact uterus and those 
who had surgical menopause (eliminating also a major source of androgen production).
Authors Response
At the time of data collection, the clinical significance of hot flashes was, and remains 
today, related largely to their impact on quality of life rather than an association with 
physical health risk (Thurston et al., 2008). As such, we did not deem collection of such 
data from our participants necessary in order to answer our research hypotheses.  More 
recently, however, research indicates underlying vascular changes among women 
reporting hot flashes. Using data from the WHI study, Rossouw and colleagues (2007) 
report that the greatest coronary heart disease risk associated with HT was concentrated 
among older women at baseline reporting moderate to severe vasomotor symptoms. As 
such, we appreciate that hot flashes may have impacted our findings, however, we are 
unable to address this concern in the manuscript beyond acknowledging this as a 
limitation. As such, the following text has been added to p17, under Limitations:
‘Recent studies indicate underlying vascular changes among women reporting hot 
flashes.18  Since we did not document whether our PMW were experiencing vaso-motor 
symptoms we were not able to determine the effects of hot flashes on our cardiovascular 
measures.’
In response to the comment regarding differences in cardiovascular responses between 
women with an intact uterus and those who had surgical menopause, we acknowledge 
that this may also have impacted our results.  Indeed, in naturally menopausal women, 
ovarian hormone biosynthesis declines progressively, providing low circulating levels of 
estrogens and androgens. In surgically menopausal woman, estrogen and androgen levels 
are rapidly and significantly reduced. However, since we demonstrate similarly low 
levels of estrogen, progesterone, testosterone, and SHBG at baseline in both groups of 
women, it is reasonable to postulate that the effects of natural versus surgical menopause 
had little or no effect on our findings.
Thurston RC, Bromberger JT, Joffe H, Avis NE, Hess R, Crandall CJ, Chang Y, Green R, Matthews KA. Beyond frequency: who is 
most bothered by vasomotor symptoms?
Menopause. 2008 Sep-Oct;15(5):841-7
Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, Barnabei VM, Ko M, LaCroix AZ, Margolis KL, Stefanick ML. 
Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007; 297: 1465–1477
Comments to Author
2) Dosage of estrogen and estrogen-progestagen combination may be important. 1 mg 
estradiol was used, which is a low dose, and some of the previous studies quoted 
probably used other hormonal preparations or other dosages. This should be mentioned in 
the Discussion. In page 7, upper sentence, the time relation between the use of 
progestagen and the performance of exercise is not so clear (in the Discussion it is 
explained in a better way [page 16]). By the way, what is "microprogesterone"? is it 
micronized progesterone?
Authors Response
The reviewer is correct in identifying that comparable previous studies looking at similar 
cardiovascular outcomes did indeed use varying hormonal preparations at differing doses 
compared to that used in the current study.  To highlight this, in the Discussion, under the 
section entitled ‘HT and Exercise Training Influences on Maximal Oxygen Uptake’, we 
have amended our manuscript to read: ‘Others have also reported no effect of varying 
hormonal preparations and dosages of HT on VO2 peak after endurance training.23, 33-35’  
We have also added the following to the Limitations section (p17): ‘It is possible our 
chosen hormone regimen may not have conferred optimal benefit to central and 
peripheral function. Alternative hormonal preparations, dosages and/or duration of 
treatment may have impacted our parameters of interest differently.’
In page 7, the time relation between use of progestin and exercise testing has been 
reworded to clarify this to the reader.  In the Methods section, under ‘Randomization’ 
(p7), the manuscript has been amended to read: ‘This medication phase was positioned at 
approximately 3 weeks, after each estradiol treatment, for a total of three months. To 
minimize the effects of the progesterone, post-HT cardiovascular measures were obtained 
during the very last week of estradiol treatment.’ 
The progesterone used in the current study was indeed a micronized progesterone
formula (Prometrium). We have amended the term ‘microprogesterone’ to read 
‘micronized progesterone’. 
Comments to Author
3) If one looks at the baseline characteristics of the study group, the standard deviations 
seem very narrow for a small group. Same goes for the cardiovascular reactions. There 
should have been a higher variance in age, height, BMI, etc if women were randomly 
selected.
Authors Response
The variance reported in the baseline characteristics of the study groups are standard 
error of the mean rather than standard deviation.  As such, the variance appears low.  For 
example, age of the N-HT study group is reported as 58 ± 2 yrs (mean ± SEM).  If 
reported as mean ± SD, the values would appear as 58 ± 6 yrs.
Comments to Author
4) Results show only the comparison of baseline versus post-training values at 30W, 
45W, 60W. It would be interesting to see the resting results as well.
Authors Response
The authors thank the reviewer for their comment. However, since the novelty of the 
study is centred around the effects of HT on submaximal cardiovascular hemodynamics, 
resting data for the cardiovascular measures were not reported.  Further, we (Kirwan et 
al., 2004) and others (Snabes et al., 1997) have previously demonstrated no effect of 
short-term HT on resting indices of cardiovascular function in healthy postmenopausal 
women.  As such, resting data was deemed unnecessarily repetitive and inconsistent with 
the focus of the current research hypotheses, and respectfully suggest its inclusion would 
not really add to the message.
Kirwan LD, MacLusky NJ, Shapiro HM, Abramson BL, Thomas SG, Goodman JM.  Acute and chronic effects of hormone 
replacement therapy on the cardiovascular system in healthy postmenopausal women.  J Clin Endocrinol Metab. 2004 
Apr;89(4):1618-29
Snabes MC, Payne JP, Kopelen HA, Dunn JK, Young RL, Zoghbi WA. Physiologic estradiol replacement therapy and cardiac 
structure and function in normal postmenopausal women: a randomized, double-blind, placebo-controlled, crossover trial.
Obstet Gynecol. 1997 Mar;89(3):332-9
Comments to Author
5) Following the comments made by the investigators in the Limitations section, perhaps 
the consequences of acute and chronic hormone use on exercise parameters should be 
mentioned too.
Authors Response
We have added the following to the Limitations section so as to mention the potential 
consequences of acute versus chronic HT on exercise parameters: ‘It is also important to 
note that different hormonal preparations, dosages and/or duration of treatment may have 
impacted our exercise parameters differently to that observed in the current study.’
Comments to Author
6) A minor comment: authors should carefully check the references: for example, ref. 20 
is not completed; ref 1+22 - JAMA, rather than Jama. Page 13, Discussion, first line 
should read aerobic exercise is equally .
Authors Response
We thank the reviewer for reporting these referencing errors.  The references have been 
checked and have been amended where necessary.
In response to the Discussion comment, the authors believe it is important to be specific 
and state the type and duration of training that affected our results. 
Reviewer 2
General Comments to Author
The authors compared the effects of a 12-week endurance training program (walking 5 
days per week at 70-80 % peak heart rate) on submaximal cardiovascular responses in 
healthy overweight and sedentary postmenopausal women being on vs. off hormone 
therapy (HT). The main focus of this paper was to verify whether HT users confers better 
improvements to central and peripheral measures of cardiovascular function compared to
non users. Results show i) decreases in oxygen consumption and heart rate but unaltered 
stroke volume, cardiac output and total peripheral resistance, and ii) increases in peak 
oxygen uptake and oxygen consumption at the ventilatory threshold, during submaximal 
exercise performed on cycle ergometer, in both groups. The main conclusion of the 
present study is that short term HT use does not seem to influence cardiovascular 
responses after 12 weeks of aerobic training. Data presented in this manuscript are of 
great interest in the field of cardiovascular adaptations to physical exercise. 
Authors Response to General Comments
We thank the reviewer for their thoughtful comments.
Comments to Author
Although stated as a limit of the study (p 17), this reviewer has some concerns about the 
lack of a non exercising group on HT which will allow the authors to conclude on the 
potential effects of HT use (even at short term) alone on the cardiovascular function of 
postmenopausal women.
Authors Response
Indeed, as acknowledged in the Limitations section of the manuscript, in the absence of a 
HT group only we were not able to determine whether submaximal cardiovascular 
hemodynamics were impacted independent of exercise training.  Our decision to exclude 
this group in the current study was based on our previous work demonstrating unaltered 
central cardiovascular function in response to 12 weeks of HT in healthy postmenopausal 
women (Kirwan et al., 2004).  To further explain our reason for not including a HT-only 
group in the current study, we have added the following to the end of the Study 
Population section: ‘Since we have previously demonstrated unaltered central 
cardiovascular function during submaximal aerobic exercise in response to 12 weeks of 
HT alone in healthy PMW,12 we did not examine the independent effects of HT in the 
current study.’      
Kirwan LD, MacLusky NJ, Shapiro HM, Abramson BL, Thomas SG, Goodman JM.  Acute and chronic effects of hormone 
replacement therapy on the cardiovascular system in healthy postmenopausal women.  J Clin Endocrinol Metab. 2004 
Apr;89(4):1618-29
Comments to Author
According to this referee, data recorded at 45 W are not necessary (Table 3) as they did 
not add substantial information on the outcome variables of this study.
Authors Response
Data recorded at 45W have been removed from Table 3.
Comments to Author
This reviewer has also some concerns concerning compliance to the aerobic training 
program as it was apparently not under supervision (p 10). This issue should be discussed 
as another limit of the study.
Authors Response
Exercise training sessions were supervised (at least) once per week only.  To address this
concern the following has been added to the Limitations section of the manuscript: 
‘Although frequency, distance walked and exercise intensity were not reported to be 
different between the groups, absence of full supervision of the exercise training sessions 
may also have affected our findings.’
Reviewer 3
Comments to Author
Statistical review: In a randomized trial, the appropriate analyses are intention to treat. 
The 14 subjects who dropped out of the study should be included in at least some
analyses. Also, of the 14 subjects who dropped out, please state how many were on HT 
and how many on placebo.
Authors Response
Whilst the divide between HT and placebo dropouts were similar (n= 8, n=6, 
respectively), we followed conventional methods used in most exercise-intervention 
studies which does not use the intention-to-treat principle. We certainly agree that an 
intent-to-treat design is a powerful approach when, for example, an effective treatment 
arrests progression of disease during its administration. Thus, a patient benefits long after 
the patient becomes noncompliant or the treatment is terminated. Therefore, in this 
example, the observations from the last patient evaluation are advantageous. However, 
our primary question was whether or not HT influenced the exercise training response, 
with exercise training being the primary intervention. Since most dropouts from training 
studies (and ours) are not due to the intervention per se, there is little bias contributed 
from a dropout, mostly due to the fact that the primary endpoints of ‘exercise adaptation’ 
are not realized (e.g. increased VO2max) without it. Moreover, in the present study, 
dropouts occurred within the first 1/3 of the study and were related to lack of 
time/commitment (n=6 exercise, n=5 placebo) and injury unrelated to exercise (n=2 in 
exercise group, n=1 placebo group), further limiting any possible carry-over effect. Given 
that the dropouts were a) similar in number and cause in both groups, b) occurred very 
early in the training program, and c) a failure to exercise would preclude the primary 
treatment effect, we are confident our statistical analysis did not introduce unwarranted 
bias in general, and increase the chance of committing a type 1 error, in particular.
Comments to Author
Please include in the Methods a description of how the appropriate sample size was 
chosen, and the statistical power to detect effects.
Authors Response
A description of how the appropriate sample size was chosen and the statistical power to 
detect effects has been added to the Methods section, as follows: ‘The following 
calculation was used to determine the number of observations needed to provide an 80% 
probability of finding differences of 1.5 standard deviations in two-sample tests 
confirming the effects of HT and exercise at a significance level of 0.05 level (Diamond, 
1981):  
n = 2 * (tdf=21α=0.05 + t
df=21
β=0.20)
2 * (SD/d)2 = 2 * (2.08 + 1.32)2 * (1/1.5)2 = 10’
Diamond WJ 1981 Practical experiment designs for engineers and scientists. Belmont, CA: Lifetime 
Learning Publications
Comments to Author
A repeated measures ANOVA would provide more power than the t-tests used in the 
analyses presented.
Authors Response
The authors acknowledge that a repeated measures ANOVA would provide more power 
than multiple t-tests using Bonferroni correction. However, we had decided that that in 
light of this being an interventional study, particularly a drug interventional study, we 
were advised to use a more conservative method of analyses.  As such, t-tests using a 
Bonferroni correction was chosen.
Comments to Author
The authors appropriately discuss the small sample size as a study limitation. However, 
their conclusions are fairly definitive, considering the small sample size. Please revise the 
study conclusions to be much more cautious, and please do not make any clinical 
recommendations based on this small study.
Authors Response
The study conclusion has been amended accordingly to be more cautious and to remove 
any clinical recommendations. Incidentally, training studies examining dose-response 
with, or without control groups are commonly reported using samples of this size based 
upon the aforementioned sample-size determination. Although larger samples are 
obviously preferred, we and many others would suggest that training studies are more 
challenging to complete than drug-intervention studies given recruitment and compliance 
issues.
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